A Phase IIIB, Randomized, Open-Label, Multicenter Study of the Safety and Efficacy of GW433908 700mg BID plus ritonavir 100mg BID Versus Lopinavir/ritonavir 400mg/100mg BID when Administered in Combination with the Abacavir/Lamivudine 600mg/300mg Fixed-Dose Combination Tablet QD in Antiretroviral-Nave HIV-1 Infected Adults Over 48 Weeks

INTERVENTION:

Product Name: ABACAVIR/LAMIVUDINE FIX DOSE COMBINATION Product Code: ABC/3TC FDC Pharmaceutical Form: Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 600‐ Product Name: FOSAMPRENAVIR Product Code: GW433908 Pharmaceutical Form: Tablet Current Sponsor code: GW433908 FOSAMPRENAVIR Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 700‐ Trade Name: KALETRA*2FL 90CPS MOLLI Pharmaceutical Form: Capsule, soft INN or Proposed

INN:

Lopinavir Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 166‐

CONDITION:

HIV Infection

PRIMARY OUTCOME:

Main Objective: Primary end point(s): Secondary Objective:

INCLUSION CRITERIA:

Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18‐64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range